These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 16015592

  • 1. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
    Hara T, Kouno J, Nakamura K, Kusaka M, Yamaoka M.
    Prostate; 2005 Nov 01; 65(3):268-75. PubMed ID: 16015592
    [Abstract] [Full Text] [Related]

  • 2. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M.
    Cancer Res; 2003 Jan 01; 63(1):149-53. PubMed ID: 12517791
    [Abstract] [Full Text] [Related]

  • 3. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O.
    Cancer Res; 2005 Nov 01; 65(21):9611-6. PubMed ID: 16266977
    [Abstract] [Full Text] [Related]

  • 4. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 5. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z.
    Prostate; 2006 Mar 01; 66(4):413-20. PubMed ID: 16302272
    [Abstract] [Full Text] [Related]

  • 6. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y, Sasaguri T, Matsumoto T.
    Cancer Invest; 2007 Feb 01; 25(1):32-7. PubMed ID: 17364555
    [Abstract] [Full Text] [Related]

  • 7. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y.
    Prostate; 2010 Apr 01; 70(5):457-66. PubMed ID: 19902465
    [Abstract] [Full Text] [Related]

  • 8. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.
    Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040
    [Abstract] [Full Text] [Related]

  • 9. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
    Urushibara M, Ishioka J, Hyochi N, Kihara K, Hara S, Singh P, Isaacs JT, Kageyama Y.
    Prostate; 2007 Jun 01; 67(8):799-807. PubMed ID: 17373727
    [Abstract] [Full Text] [Related]

  • 10. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC.
    Prostate; 2010 Feb 01; 70(2):179-89. PubMed ID: 19790234
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
    Kawabata R, Oie S, Oka T, Takahashi M, Kanayama H, Itoh K.
    Int J Oncol; 2011 Mar 01; 38(3):665-76. PubMed ID: 21243325
    [Abstract] [Full Text] [Related]

  • 16. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
    Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP.
    Cancer Res; 1999 Jun 01; 59(11):2511-5. PubMed ID: 10363963
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.
    Carcinogenesis; 2008 Jun 01; 29(6):1148-56. PubMed ID: 18487223
    [Abstract] [Full Text] [Related]

  • 18. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.
    Eder IE, Haag P, Basik M, Mousses S, Bektic J, Bartsch G, Klocker H.
    Mol Carcinog; 2003 Aug 01; 37(4):181-91. PubMed ID: 12891627
    [Abstract] [Full Text] [Related]

  • 19. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G.
    Prostate; 2005 May 01; 63(2):155-68. PubMed ID: 15486991
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.